SGLT-2 receptor inhibitors: An opportunity to revise our therapeutic strategy for type 2 diabetes?

被引：4
作者：
Bonnet, Fabrice [1 ]
Scheen, Andre J. [2 ,3 ]
机构：
[1] Univ Rennes 1, CHU Rennes, Inserm UMR 991, Serv Endocrinol Diabetol, Rennes, France
[2] Univ Liege, CIRM, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[3] Univ Liege, CHU Sart Tilman, Dept Med, Div Clin Pharmacol, Liege, Belgium
来源：
DIABETES & METABOLISM | 2014年 / 40卷
关键词：
GLYCEMIC CONTROL; DOUBLE-BLIND; ADD-ON; METFORMIN; DAPAGLIFLOZIN; SITAGLIPTIN; MANAGEMENT; PLACEBO;
D O I：
10.1016/S1262-3636(14)72688-6
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S1 / S3
页数：3
相关论文
共 17 条
  • [1] Composite endpoints in trials of type-2 diabetes
    Einarson, T. R.
    Garg, M.
    Kaur, V.
    Hemels, M. E. H.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (06) : 492 - 499
  • [2] SGLT-2 inhibition in patients with kidney disease
    Gilbert, R. E.
    [J]. DIABETES & METABOLISM, 2014, 40 : S23 - S27
  • [3] Hansen L, 2014, DIABETOLOGIA, V57, pS8
  • [4] Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
    Inzucchi, S. E.
    Bergenstal, R. M.
    Buse, J. B.
    Diamant, M.
    Ferrannini, E.
    Nauck, M.
    Peters, A. L.
    Tsapas, A.
    Wender, R.
    Matthews, D. R.
    [J]. DIABETOLOGIA, 2012, 55 (06) : 1577 - 1596
  • [5] Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
    Lavalle-Gonzalez, F. J.
    Januszewicz, A.
    Davidson, J.
    Tong, C.
    Qiu, R.
    Canovatchel, W.
    Meininger, G.
    [J]. DIABETOLOGIA, 2013, 56 (12) : 2582 - 2592
  • [6] Patel S, 2014, DIABETOLOGIA, V57, pS7
  • [7] Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence
    Scheen, A. J.
    Paquot, N.
    [J]. DIABETES & METABOLISM, 2014, 40 : S4 - S11
  • [8] Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
    Scheen, A. J.
    Charbonnel, B.
    [J]. DIABETES & METABOLISM, 2014, 40 (03) : 176 - 185
  • [9] Metformin revisited: A critical review of the benefit-risk balance in at-risk patients with type 2 diabetes
    Scheen, A. J.
    Paquot, N.
    [J]. DIABETES & METABOLISM, 2013, 39 (03) : 179 - 190
  • [10] Scheen AJ, 2014, DRUGS IN PRESS
12